French startup Elkedonia secured €11 million in seed funding to advance its ELK-1 inhibitor targeting refractory depression. ELK-1 influences neuroplasticity and reward circuits implicated in mood disorders. This investment supports progression toward clinical evaluation and highlights a novel approach in neuropsychiatric therapeutics.